We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.82B
AUM Growth
+$974M
Cap. Flow
+$85.6M
Cap. Flow %
0.97%
Top 10 Hldgs %
37.09%
Holding
149
New
20
Increased
26
Reduced
29
Closed
13

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$111M
2
AGN.PRA
Allergan plc
AGN.PRA
+$73.1M
3
MRK icon
Merck
MRK
+$69.9M
4
AET
Aetna Inc
AET
+$63.6M
5
VTRS icon
Viatris
VTRS
+$52.4M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$148M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72.3M
3
AGN
Allergan plc
AGN
+$68.1M
4
ISRG icon
Intuitive Surgical
ISRG
+$67.6M
5
SHPG
Shire pic
SHPG
+$53.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.96%
2 Financials 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
101
CRISPR Therapeutics
CRSP
$4.68B
$8.1M 0.09%
372,191
– –
IMMU
102
DELISTED
Immunomedics Inc
IMMU
$7.97M 0.09%
1,232,100
-2,569,900
-68% -$13M
WMGI
103
CALL
DELISTED
Wright Medical Group Inc
WMGI
$7.78M 0.09%
+250,000
New +$6.78M
NVRO
104
DELISTED
NEVRO CORP.
NVRO
$7.29M 0.08%
+77,800
New +$7.05M
TSRO
105
DELISTED
TESARO, Inc.
TSRO
$7.26M 0.08%
47,200
– –
SNDX icon
106
Syndax Pharmaceuticals
SNDX
$1.74B
$6.65M 0.08%
484,800
-272,565
-36% -$2.83M
ALXN
107
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$6.06M 0.07%
50,000
-50,000
-50% -$6.45M
ZBH icon
108
Zimmer Biomet
ZBH
$18.5B
$5.98M 0.07%
50,470
– –
NERV icon
109
Minerva Neurosciences
NERV
$199M
$5.71M 0.06%
88,038
+18,513
+27% +$1.44M
SRRA
110
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$5.67M 0.06%
+92,593
New +$5.38M
BMY icon
111
CALL
Bristol-Myers Squibb
BMY
$130B
$5.44M 0.06%
+100,000
New +$5.48M
RDHL
112
Redhill Biopharma
RDHL
$4.44M
$5.42M 0.06%
565
– –
NVTA
113
DELISTED
Invitae Corporation
NVTA
$5.05M 0.06%
456,666
– –
LUMO
114
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$4.82M 0.05%
+22,222
New +$3.17M
AFMD
115
DELISTED
Affimed
AFMD
$4.64M 0.05%
201,890
-135,610
-40% -$2.98M
SIEN
116
DELISTED
Sientra, Inc.
SIEN
$4.4M 0.05%
52,226
-22,031
-30% -$1.94M
ALNY icon
117
Alnylam Pharmaceuticals
ALNY
$38.5B
$4.21M 0.05%
+82,200
New +$3.8M
ROKA
118
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$3.18M 0.04%
893,470
– –
XENE icon
119
Xenon Pharmaceuticals
XENE
$6.28B
$2.54M 0.03%
634,812
-365,188
-37% -$2.87M
CLSD
120
DELISTED
Clearside Biomedical
CLSD
$2.38M 0.03%
20,000
– –
BHC icon
121
Bausch Health
BHC
$1.69B
$2.15M 0.02%
194,900
– –
AMRN
122
Amarin Corp
AMRN
$293M
$1.12M 0.01%
17,500
– –
NVLN
123
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$1.07M 0.01%
100,000
– –
MRNS
124
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1M 0.01%
141,900
– –
BLRX
125
BioLineRX
BLRX
$12.2M
$998K 0.01%
1,731
– –
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2017 Portfolio in Review

As of Q1 2017, OrbiMed held 149 positions worth $8.82B, up 12% from $7.85B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q1 2017 filing shows 20 new, 26 increased, 29 reduced and 13 closed positions. Its largest new stake was Centene: 3,311,400 shares worth $118M. The largest sale was Amgen, an estimated $148M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q1 2017 buy was Centene: 3,311,400 shares worth $118M.
  • OrbiMed added most to Merck in Q1 2017, an estimated $69.9M increase.
  • OrbiMed's biggest Q1 2017 reduction was Amgen, cutting an estimated $148M.
  • OrbiMed fully exited Molina Healthcare in Q1 2017, selling an estimated $26.9M.
  • OrbiMed's ten largest holdings make up 37% of its $8.82B portfolio in Q1 2017.
  • OrbiMed opened 20 new positions and closed 13 in Q1 2017.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $8.82B.

Based on OrbiMed's 13F filing for Q1 2017, filed 15 May 2017.